Prestige Consumer Healthcare (PBH) Other Non-Current Liabilities (2013 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Other Non-Current Liabilities came in at $5.7 million in Q4 2025, up 14.28% year-on-year from $5.0 million in Q4 2024, and up 6.84% quarter-over-quarter from $5.4 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Other Non-Current Liabilities (2013 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $5.7 million for Q4 2025.
- On a quarterly basis, Other Non-Current Liabilities rose 14.28% year-over-year to $5.7 million in Q4 2025; TTM through Dec 2025 was $5.7 million, a 14.28% increase from a year earlier, with the FY2025 full-year figure at $5.4 million, down 41.31% from the prior year.
- Other Non-Current Liabilities grew to $5.7 million in Q4 2025 per PBH's latest filing, from $5.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $9.2 million in Q1 2024 and bottomed at $5.0 million in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $8.3 million (2021), against an average of $7.4 million.
- Across the five-year window, Other Non-Current Liabilities slumped 66.15% in 2021 and advanced 14.28% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $8.4 million in 2021, then rose by 5.21% to $8.9 million in 2022, then rose by 0.53% to $8.9 million in 2023, then sank by 43.61% to $5.0 million in 2024, then grew by 14.28% to $5.7 million in 2025.
- Per Business Quant, the three latest PBH Other Non-Current Liabilities figures stand at $5.7 million (Q4 2025), $5.4 million (Q3 2025), and $5.4 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | 5.41 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Dec 31, 2024 | 5.03 Mn |
| Sep 30, 2024 | 5.12 Mn |
| Jun 30, 2024 | 5.14 Mn |
| Mar 31, 2024 | 9.19 Mn |
| Dec 31, 2023 | 8.92 Mn |
| Sep 30, 2023 | 8.90 Mn |
| Jun 30, 2023 | 8.18 Mn |
| Mar 31, 2023 | 8.17 Mn |
| Dec 31, 2022 | 8.87 Mn |
| Sep 30, 2022 | 8.88 Mn |
| Jun 30, 2022 | 8.92 Mn |
| Mar 31, 2022 | 7.48 Mn |
| Dec 31, 2021 | 8.43 Mn |
| Sep 30, 2021 | 8.49 Mn |
| Jun 30, 2021 | 8.56 Mn |
| Mar 31, 2021 | 8.61 Mn |